Archive for December, 2007

Glaucoma medications costs

Friday, December 28th, 2007

Eye surgeryIn the United States, the management of glaucoma costs about $2.5 billion per year. Of the $1.9 billion in direct costs, glaucoma medications account for an estimated 38% to 52% of the total. In an article published in the January 2008 issue of the American Journal of Ophthalmology, researchers from The Texas A&M University System Health Science Center College of Medicine, Temple, Texas; analyzed the economics of medically managing glaucoma. The yearly costs to patients of various topical glaucoma medications were calculated and significant price differences and increases in cost over time were found.

The researchers looked at four classes of pharmaceuticals; ?-blockers, prostaglandins, ?2-agonists and carbonic anhydrase inhibitors. They compared both brand-name and generic formulations, evaluated how accurately the bottles were filled and how accurately the medications could be dispensed by patients. Using results from earlier studies, the increases in Average Wholesale Prices (AWP) were also evaluated from 1999 through 2006.

Nonselective ?-blockers remain the most inexpensive class of glaucoma medications. For all categories of drugs, calculated yearly cost ranged from $150.81 for generic timolol maleate 0.5% (?-blocker), to $697.42 for Cosopt (combination formulation), to as high as $873.98 for a three-times-daily dose of Alphagan P 0.15% (?2-agonist). Among brand name ?-blockers, yearly cost ranged between $203.47 for Timoptic 0.5% and $657.24 for Betoptic S. Generic ?-blockers consistently were more economical than their brand-name counterparts. Yearly cost of prostaglandin analogs ranged from $427.69 for Travatan to $577.62 for Lumigan. The two carbonic anhydrase inhibitors, Azopt and Trusopt, yielded similar economic profiles. The generic selective ?2-agonist brimonidine tartrate 0.2% costs approximately $352.89 and $529.34 per year for the respective two and three drops daily per eye regimens.

AWP trends through two periods, 1999 to 2006 and 2002 to 2006, showed significant increases, even within a category. For example, in the ?-blockers, Betoptic S increased nearly 100 % from 1999 to 2006, while Timoptic, increased only 11.7 %. In the period 2002 to 2006, the AWP of Timoptic remained constant.

Writing in the article, Steven D. Vold states, “Physicians consider many factors when treating patients with glaucoma. Ultimately, the goal of eye care providers is to give the best, most cost-effective care to their patients. Our study addresses the calculated cost per year passed on to the patient for single medication treatment plans…As newer medications and treatment schemes are introduced, future studies will be needed to update the rapidly changing economic information pertaining to the medical management of glaucoma.”

Glaucoma treatment cannot cure the condition, but it can dramatically slow or temporarily halt its progress. Glaucoma can be treated with either medication or surgery. Both of these treatments are aimed at lowering intraocular pressure (IOP), or pressure within the eye. In the United States, medications are usually the first-line of glaucoma treatment. If this fails, then glaucoma surgery is the next treatment considered.

Glaucoma Medications

Glaucoma medications are either oral or topical. Topical medications such as eye drops, eye ointments, or inserts (strips of medication inserted in the corner of the eye) work to reduce IOP either by increasing the outflow of fluid from the eye or by reducing the amount of fluid produced by the eye. To learn more about the condition, examine the risk factors and symptoms of glaucoma. It is important to tell all of your doctors about any glaucoma medications that you are using. In order for these medications to work, you must take them regularly and continuously as they were prescribed.

Topical Glaucoma Medications

There are five types of topical glaucoma medications, each achieving different purposes:

  • Miotics increase the outflow of fluid. These include Isopto® Carpine, Ocusert®, Pilocar®, and Pilopine®.
  • Epinephrines increase the outflow of fluid. These include Epifrin® and Propine®.
  • Beta-blockers reduce the amount of fluid. These include Betagan®, Betimol®, Betoptic®, Ocupress®, Optipranalol®, and Timoptic®.
  • Carbonic-anhydrase inhibitors and alpha-adrenergic agonists reduce the amount of fluid present. These include Alphagan®, Iopidine®, and Trusopt®.
  • Prostaglandin analogs increase the outflow of fluid through a secondary drainage route. These include Lumigan®, Rescula®, Travatan®, and Xalatan®.

Oral Glaucoma Medications

Your ophthalmologist can also prescribe oral medications to treat glaucoma. Carbonic anhydrase anhibitors are the oral medications most commonly used in the treatment of glaucoma. These include Daranide®, Diamox®, and Neptazane®.

Patients will be started on one medication or a combination of drugs. If a patient does not respond to one type of drug, he or she can be switched to another until all possibilities have been exhausted. Once this happens, the ophthalmologist may recommend glaucoma surgery.
Glaucoma Surgery

For patients who still have an elevated IOP after attempting glaucoma treatment through medication, an ophthalmologist may recommend either laser or conventional surgery.

Glaucoma Laser Surgery

There are three types of glaucoma laser surgery that can be performed in the doctor’s office:

Trabeculoplasty

Trabeculoplasty uses a laser to burn tissue from the trabecular meshwork, a structure within the eye that controls the flow of fluid. This procedure increases the aqueous outflow in the area surrounding the laser spot, relieving pressure within the eye. Pressure is reduced in 60 to 70 percent of the patients in whom a laser trabeculoplasty is performed. This type of glaucoma laser surgery is used to treat patients with open-angle glaucoma.

Iridotomy

Closed-angle glaucoma occurs when the angle between the iris and the cornea in the eye is too small. This causes the iris to block fluid drainage, increasing inner eye pressure. Iridotomy glaucoma laser surgery makes a small hole in the iris, allowing it to fall back from the fluid channel so fluid can drain.

Cyclophotocoagulation

Cyclophotocoagulation uses a laser to burn ciliary tissue, which decreases the production of fluid in the eye. The procedure, performed under local anesthesia, has only recently become available to glaucoma patients to reduce the intraocular pressure. This type of glaucoma laser surgery is used to treat patients who have failed to respond to other types of glaucoma surgery. Many patients will require more than a single treatment. The procedure appears to have significant success and relatively low risk.

Conventional Glaucoma Surgery

If laser surgery fails to lower IOP, the surgeon may recommend conventional glaucoma surgery, known as trabeculectomy or filtering surgery. This is an outpatient procedure involving the removal of a tiny piece of the eye under the eyelid. This conventional glaucoma surgery creates a new drainage path that increases the outflow of fluid from the eye.

Xalatan is more effective than Alphagan

Friday, December 28th, 2007

XalatanStudy Compares Two Common Glaucoma Medications

A multinational study group including ophthalmologists from Finland, Germany, Ireland, Spain, and the United Kingdom recently reported the results of their study comparing Xalatan (latanoprost) and Alphagan (brimonidine) at the European Glaucoma Society meeting. The study group sought to determine both effectiveness and safety of the two commonly used glaucoma drops. Hannu Uusitalo, MD, ophthalmologist at the University Hospital, Tampere, Finland, presented the results.

The Study Protocol

A total of 379 patients with glaucoma or ocular hypertension (high eye pressure) were enrolled in the study and randomly assigned to receive one of the two drugs. The ophthalmologists were masked as to which agent individual patients were receiving to prevent observer bias. Baseline eye pressure measurements were taken prior to using the drops. The measurements were repeated at 2 weeks, 3 months, and 6 months after the patients had used the medication. Pressure readings were taken at 10:00 a.m. and 5:00 p.m. on examination days.

Adverse Events

Six months after the initiation of treatment, only 5 patients in the Xalatan group had withdrawn due to either side effects or uncontrolled eye pressure versus 53 patients in the Alphagan group. In the Alphagan group, 14 had ocular allergies to the medicine, 12 had uncontrolled eye pressure, and the remainder withdrew due to side effects or compliance related issues.

Effectiveness Controlling Eye Pressure

Patients in the Xalatan and Alphagan study groups had substantial decreases in eye pressure during the study; however, the group taking Xalatan had statistically significantly lower eye pressures than the Alphagan group. Those in the Xalatan group had a 28% reduction of eye pressure compared with a 21% reduction in the Alphagan group.

Furthermore, a target eye pressure of less than 18 mm Hg was achieved in 57% of the Xalatan patients versus 33% of the Alphagan patients. A pressure reduction of 30% or more was achieved in 42% of the Xalatan patients versus 22% of the Alphagan patients. Only 12% of the patients in the Xalatan group had a pressure reduction from baseline of less than 15%, compared to 32% of patients in the Alphagan group.

Conclusions

This study clearly shows Xalatan lowered intraocular pressure more effectively than Alphagan and had fewer side effects. Furthermore, since Xalatan only needs to be instilled once each day, patients may find it easier to use instead of Alphagan, which is used twice each day.

Despite the study results, patients should realize that glaucoma medications are tailored to the individual and the physician considers many factors when selecting the appropriate medication. This relatively short-term study did not assess the effect of treatment on the optic nerve or the peripheral vision with visual field testing, both key parameters when assessing treatment effect. Finally, as one can see from the above study results, the effect of glaucoma medication varies significantly from one individual to another, both in lowering pressure and side-effects. Therefore, it is certainly possible that Xalatan may be less effective than Alphagan in a given individual. This is why many ophthalmologists treat one eye initially, monitoring the effectiveness of the medication against the patient’s untreated eye.

What is Xalatan?

Xalatan reduces pressure in the eye by increasing the amount of fluid that drains from the eye.
Xalatan is used to treat certain types of glaucoma and other causes of high pressure inside the eye.

Xalatan may also be used for other purposes not listed in this medication guide.

Important information about Xalatan

Do not use Xalatan while you are wearing contact lenses. This medication may contain a preservative that can be absorbed by soft contact lenses. Wait at least 15 minutes after using Xalatan before putting your contact lenses in.

Xalatan may cause a gradual change in the color of your eyes or eyelids and lashes, as well as increased growth or thickness of your eyelashes. These color changes, usually an increase in brown pigment, occur slowly and you may not notice them for months or years. Color changes may be permanent even after your treatment ends, and may occur only in the eye being treated. This could result in a cosmetic difference in eye or eyelash color from one eye to the other.
Do not allow the dropper to touch any surface, including the eyes or hands. If the dropper becomes contaminated it could cause an infection in your eye, which can lead to vision loss or serious damage to the eye.

After using Xalatan, wait at least 5 minutes before using any other eye drops that your doctor has prescribed.

Before using Xalatan

Do not use Xalatan if you are allergic to latanoprost.

Before using Xalatan, tell your doctor if you are allergic to any drugs, or if you have swelling or infection of your eye.

Xalatan may cause a gradual change in the color of your eyes or eyelids and lashes, as well as increased growth or thickness of your eyelashes. These color changes, usually an increase in brown pigment, occur slowly and you may not notice them for months or years. Color changes may be permanent even after your treatment ends, and may occur only in the eye being treated. This could result in a cosmetic difference in eye or eyelash color from one eye to the other.

FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether Xalatan passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I use Xalatan?
Do not use Xalatan while you are wearing contact lenses. This medication may contain a preservative that can be absorbed by soft contact lenses. Wait at least 15 minutes after using Xalatan before putting your contact lenses in.

Use this medication exactly as it was prescribed for you. Do not use the medication in larger amounts, or use it for longer than recommended by your doctor. Follow the instructions on your prescription label.

What is Alphagan?

Alphagan reduces the amount of fluid in the eye, which decreases pressure inside the eye.
Alphagan is used to treat open-angle glaucoma or ocular hypertension (high pressure inside the eye).

Alphagan may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about Alphagan?
Do not use Alphagan if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days.

Before using Alphagan, tell your doctor if you have kidney or liver disease, heart disease, high blood pressure, circulation problems such as Raynaud’s or Buerger’s disease, or a history of fainting or low blood pressure.

Do not use Alphagan while you are wearing contact lenses. This medication may contain a preservative that can be absorbed by soft contact lenses. Wait at least 15 minutes after using Alphagan before putting your contact lenses in.

Do not allow the dropper tip to touch any surface, including the eyes or hands. If the dropper becomes contaminated it could cause an infection in your eye, which can lead to vision loss or serious damage to the eye.
What should I discuss with my healthcare provider before using Alphagan?

You should not use Alphagan if you are allergic to brimonidine.
Do not use Alphagan if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days.

Before using Alphagan, tell your doctor if you have:

  • kidney disease;
  • liver disease;
  • heart disease or high blood pressure;
  • circulation problems, such as Raynaud’s syndrome or Buerger’s disease; or
  • a history of fainting or low blood pressure.

If you have any of these conditions, you may need a dose adjustment or special tests to safely use Alphagan.

FDA pregnancy category B. This medication is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether Alphagan passes into breast milk or if it could harm a nursing baby. Do not use Alphagan without telling your doctor if you are breast-feeding a baby.

How should I use Alphagan?

Use this medication exactly as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended. Follow the directions on your prescription label.

Wash your hands before using the eye drops. Do not use Alphagan while you are wearing contact lenses. This medication may contain a preservative that can be absorbed by soft contact lenses. Wait at least 15 minutes after using Alphagan before putting your contact lenses in.

Putting in Eye Drops - Tips

Friday, December 28th, 2007

Eye drops tips

Remember . . .

  • When putting drops into your eyes, follow doctor’s orders.
  • Be sure your doctor knows about any other drugs you may be taking (including over-the-counter items like vitamins and aspirin) and about any allergies you may have.
  • Wash your hands before putting eye drops into your eyes.
  • Be careful NOT to touch the tip of the dropper to any part of your eye.
  • Make sure the dropper stays clean.
  • If you are putting in more than one drop or more than one type of eye drop, wait five minutes before putting the next drop in. This will keep the first drop from being washed out by the second before it has had time to work.
  • Store the eye drops and all medicines out of reach of children.

Steps for Putting in Eye Drops

  1. Start by tilting your head backward while sitting, standing, or lying down. With your index finger placed on the soft spot just below the lower lid, gently pull down to form a pocket.
  2. Let a drop fall into the pocket
  3. Slowly let go of the lower lid. Blinking a few times is all right, but try not to shut your eyes tight or squint. This may push the drops out of your eye.
  4. Gently press on the inside corner of your closed eyes with your index finger and thumb for two to three minutes. This will help keep any drops from getting into your system and keep them in your eye, where they are needed.
  5. Blot around your eyes to remove any excess.

If you are still having trouble putting eye drops in, here are some additional tips that may help.

If your hands are shaking:

  • Try approaching your eye from the side so you can rest your hand on your face to help steady your hand.
  • If shaky hands are still a problem, you might try using a 1- or 2-pound wrist weight (you can get these at any sporting goods store). The extra weight around the wrist of the hand you are using can decrease mild shaking.

If you are having trouble getting the drop into your eye:

  • It may be easier to tell if the drop has gone into your eye if you keep your drops in the refrigerator. Your eye will feel the liquid when it is cold better than if it is at room temperature.
  • If you are still not sure the drop actually got in your eye, put in another drop. The eyelids can hold only about one drop, so any excess will just run out of the eye. It is better to have excess run out than to not have enough medication in your eye.
  • If pulling the lower lid out to create a pocket is not working, try this. With your head turned to the side or lying on your side, close your eyes. Place a drop in the inner corner of your eyelid (the side closest to the bridge of your nose). By opening your eyes slowly, the drop should fall right into your eye.

(more…)

Tykerb (lapatinib) kills breast cancer

Wednesday, December 26th, 2007

GlaxoSmithKline Tykerb (lapatinib)GlaxoSmithKline Plc announced further clinical trial results on Sunday underlining the ability of a drug combination including its product Tykerb to fight breast cancer that has spread to the brain.

An extension to an earlier Phase II study involving 49 patients showed 20 percent of those receiving a mix of Tykerb and Roche’s Xeloda experienced at least a 50 percent volume reduction in measurable brain metastases.

The finding is significant because up to a third of women with HER2-positive metastatic breast cancer may develop brain metastases, which occur when cancer spreads from its original site.

The results were presented at the San Antonio Breast Cancer Symposium in San Antonio, Texas.

Tykerb, a once-daily pill, was approved by U.S. regulators in March and won a conditional green light from the European Medicines Agency on Friday.

It is recommended as a treatment, in combination with Xeloda, for patients with advanced or metastatic breast cancer whose tumors over-express protein HER2.

Tykerb kills breast cancer stem cells

A combination drug, Tykerb, known generically as lapatinib, appears to be able to fight breast cancer that has spread to the brain, media reported Tuesday.

For the first time, researchers have shown that the drug can slash the number of cancer stem cells in women with breast cancer, curbing tumor growth.

The latest theory of what causes cancer namely is that stem cells hiding within tumors drive their growth. Conventional treatments fail to cure cancer, according to the theory, because they are targeting the wrong cells.

Six weeks of Tykerb treatment slashed the number of breast cancer stem cells by more than half in 30 women studied, and two-thirds were cancer-free after follow-up treatment, says Jenny Chang, MD, of Baylor University in Houston.

The finding is significant because up to one third of women with HER2-positive advanced breast cancer may develop brain metastases.

About TYKERB/TYVERB(3)

TYKERB/TYVERB (lapatinib) is a first-in-class oral small-molecule inhibitor of the HER2 (ErbB2) tyrosine kinase receptor. Stimulation of HER2 is associated with cell proliferation and with multiple processes involved in tumor progression and metastases. Overexpression of this receptor has been reported in a variety of human tumors and is associated with poor prognosis and reduced overall survival. On March 13, 2007, the United States Food and Drug Administration (FDA) approved TYKERB, in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.

TYVERB has been approved in more than 15 countries, and marketing applications for TYKERB/TYVERB have been filed around the world.

About GlaxoSmithKline

GlaxoSmithKline — one of the world’s leading research-based pharmaceutical and healthcare companies — is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

How and when to take pills? Tips.

Wednesday, December 26th, 2007

Taking pills tips

Many medications, both prescription and over-the-counter, can negatively interact with foods, supplements or other drugs.

 

 

 

Here are guidelines to help prevent food-drug interactions, courtesy of the American Academy of Family Physicians:

  • Check prescription and over-the-counter drug labels to see if they contain any warnings.
  • Follow directions on all medications carefully.
  • Unless you get your doctor’s OK, never break up pills and mix them with food, and never empty capsules into food.
  • Take medications with a whole glass of water, unless your doctor has given you other instructions. Never take medications with alcohol.
  • Don’t take your medications at the same time as you take vitamins or dietary supplements.
  • Don’t mix medications in a hot drink, as the heat may affect the medication.

Taking drugs with food may take a bite out of costs

Taking an expensive breast cancer drug on a full stomach – as opposed to an empty one as prescribed – could save a patient or their health authority $1700 (?835) a month or more, according to an analysis of data from clinical trials.

The approach, which might also work for other drugs, is based on the fact that certain foods can delay the breakdown of medications in the body. Doctors stress, however, that people should not yet attempt this cost-cutting method until studies demonstrate its safety.

In general, taking pills with food against the label’s advice can lead to an overdose. For example, drinking grapefruit juice can interfere with the body’s ability to handle cholesterol-lowering statin drugs.

For this reason, pharmaceutical companies must provide the US Food and Drug Administration (FDA) with information on how eating a meal can influence the absorption of their products.

This was the case when GlaxoSmithKline sought approval for its anticancer drug lapatinib (known as Tykerb in the US and Tycerb in Europe).

Higher blood levels

Pharmaceutical companies generally tell patients in early drug trials to take the medication on an empty stomach, as this helps reduce the variables between patients.

In this instance, when researchers later conducted the food-interaction experiments involving lapatinib, they found that taking it at mealtime raised blood levels of the drug far above those shown as safe in previous trials. This meant that the drug label would have to advise patients to take the pill on an empty stomach.

The FDA approved lapatinib in March 2007 to treat breast cancers that have not responded to other medications. Specifically, the drug fights breast cancers that contain an excess of a protein called “human epidermal growth factor receptor 2″ (HER2), and have spread through the body.

This subtype of breast cancer claims the lives about 8000 to 10,000 US women each year, according to the American Cancer Society. But this help does not come cheap. Lapatinib costs a patient roughly $2900 a month, a large sum, particularly for those who lack health insurance.

Ezra Cohen and Mark Ratain at the University of Chicago, Illinois, US wondered if taking advantage of changes in lapatinib absorption after eating could reduce this cost.

Based on clinical trial data submitted to the FDA, they calculated that taking the medication with a low-fat meal or high-fat meal could increase the amount of lapatinib circulating in the blood by 1.7 and 3.3 times, respectively. Adding grapefruit juice to the mix would reduce costs further still.

“We expect that one 250 milligram lapatinib pill accompanied by food and washed down with a glass of grapefruit juice may yield plasma concentrations comparable to five 250 milligram pills on an empty stomach,” Ratain says.

People who pop a pill with a meal, but no grapefruit juice, are calculated to get the equivalent effect of three pills, and would save around $1700 a month.

Experiment warning

“It’s kind of akin to pill splitting,” says Steven Pearson, of Harvard Medical School in Boston, Massachusetts US. But he thinks the approach is unlikely to be the first choice strategy for making medicines more affordable. Pearson is working to develop a review board that would examine ways to improve cost-effectiveness of drugs in the US.

Pearson says that more sweeping changes – such as providing universal health insurance and reaching a consensus on how much patients should have to pay for meds in the first place – should take top priority.

Pharmaceutical companies argue that high drug prices result from the huge investment required in research and development. But patient advocacy groups have countered that much of the extra money goes into the pockets of shareholders, rather than into such research. They say that there is lots of room for price cutting.

While this debate continues, Cohen urges people not to experiment with taking lapatinib with meals until more research demonstrates the safety of doing so. “This is not something that we suggest people try at home. This is something that should be studied,” says Cohen, adding that an overdose of lapatinib could perhaps cause a heart attack.

He says that these types of trials will only happen if the public demands them: “In part it has to come from patient advocacy groups who say this needs to be studied.”

Cohen adds that he and his colleagues are looking at whether taking other medications, such as the immune suppressant rapamycin, with food could possibly lower drug costs.

Taking High Blood Pressure Pills at Night May Be Better for Some

Taking a blood pressure pill at bedtime instead of in the morning might be healthier for some high-risk people.

New research suggests that simple switch may normalize patterns of blood pressure in patients at extra risk from the twin epidemics of heart and kidney disease.

Why? When it comes to blood pressure, you want to be a dipper. In healthy people, blood pressure dips at night, by 10 to 20 percent. Scientists don’t know why, but suspect the drop gives arteries a little rest.

People with high blood pressure that doesn’t dip at night — the non-dippers — fare worse than other hypertension sufferers, developing more serious heart disease. Moreover, heart and kidney disease fuel each other — and the 26 million Americans with chronic kidney disease seem most prone to non-dipping. In addition to heart problems, they’re at extra risk of their kidney damage worsening to the point of dialysis.

Most blood pressure patients need two or three medications. So Italian researchers performed an easy test: They told 32 non-dippers with kidney disease to switch one of those drugs from a morning to a bedtime dose. In two months, nearly 90 percent of these high-risk patients had turned into dippers. Their nighttime blood pressure dropped an average of 7 points, without side effects or increase in daytime blood pressure.

Better, a key sign of kidney function improved significantly, too, Dr. Roberto Minutolo of the Second University of Naples reports this month in the American Journal of Kidney Diseases.

It’s the latest research in the field of chronotherapy: How our bodies’ internal rhythms make certain diseases worse at certain times of the day, and in turn affect how to time treatments.

While the Italian study is too small for proof, similar studies from Europe also back a bedtime switch for non-dippers. The work is catching the attention of U.S. hypertension specialists, and now doctors at Baltimore’s Johns Hopkins University are planning a larger study to see if a bedtime switch really could give certain people healthier hearts and kidneys.

How big a problem is non-dipping?

“I think it’s huge,” says Hopkins’ Dr. Lawrence Appel. “This is our best lead” into why black Americans with kidney disease, in particular, tend to worsen despite treatment.

Appel found 80 percent of black kidney patients in a recent study were non-dippers. Most startling, 40 percent had nighttime blood pressure that was even higher than daytime levels.

Two-thirds of chronic kidney disease patients, and at least 10 percent of the general population, are estimated to be non-dippers, says Dr. Joseph Vassalotti of the National Kidney Foundation. One theory is that their bodies have trouble excreting salt.

Yet few patients have ever heard of the problem — and few doctors know who is affected. Most people get their blood pressure checked only during the day. A 24-hour blood pressure monitor can tell but is rarely used, partly because insurance seldom pays for the extra visit to download and diagnose the readings.

And most patients who take several once-a-day pills swallow them all in the morning, meaning they all start wearing off around the same time, says Dr. Gina Lundberg of St. Joseph’s Hospital in Atlanta.

“It does make good sense to take some in the morning and some in the evening,” says Lundberg, a spokeswoman for the American Heart Association.

Everyone has an internal clock, determined by genes, that affects health. Many of these biological rhythms are circadian, meaning they fluctuate on a 24-hour cycle.

Consider how that can affect the timing of treatments. Some older “statin” pills fight cholesterol best if taken at bedtime; they target a liver enzyme that’s most active at night. Asthma attacks are more frequent at night, and the stomach secretes more heartburn-causing acid at night, affecting some patients’ dosing requirements. Researchers even are studying how to better time certain cancer chemotherapies and allergy treatments.

The best-known example: Blood pressure jumps in the early morning hours, as the awakening body produces more stress hormones. That’s also why heart attacks and strokes are most common in the morning.

The nighttime dipping problem has gotten far less attention. The new Italian study marks an important advance, says Dr. Mahboob Rahman of the University Hospitals of Cleveland.

“We know now that you can change medication timing and lower blood pressure at night,” he explains.

That doesn’t mean everyone should switch willy-nilly to bedtime dosing. Morning may be best for people on just one drug, and no one yet knows if the switch truly gives non-dippers better overall health. “That’s the million-dollar question,” Rahman cautions.

Still, Lundberg says it’s worth asking your doctor how to time doses, saying one at night for someone taking multiple medicines couldn’t hurt.

Taking pills. Timing matters!

Tuesday, December 18th, 2007

PillsTaking a blood pressure pill at bedtime instead of in the morning might be healthier for some high-risk people.

New research suggests that simple switch may normalize patterns of blood pressure in patients at extra risk from the twin epidemics of heart and kidney disease.

Why? When it comes to blood pressure, you want to be a dipper. In healthy people, blood pressure dips at night, by 10 to 20 percent. Scientists don’t know why, but suspect the drop gives arteries a little rest.

People with high blood pressure that doesn’t dip at night — the non-dippers — fare worse than other hypertension sufferers, developing more serious heart disease. Moreover, heart and kidney disease fuel each other — and the 26 million Americans with chronic kidney disease seem most prone to non-dipping. In addition to heart problems, they’re at extra risk of their kidney damage worsening to the point of dialysis.

Most blood pressure patients need two or three medications. So Italian researchers performed an easy test: They told 32 non-dippers with kidney disease to switch one of those drugs from a morning to a bedtime dose. In two months, nearly 90 percent of these high-risk patients had turned into dippers. Their nighttime blood pressure dropped an average of 7 points, without side effects or increase in daytime blood pressure.

Better, a key sign of kidney function improved significantly, too, Dr. Roberto Minutolo of the Second University of Naples reports this month in the American Journal of Kidney Diseases.

It’s the latest research in the field of chronotherapy: How our bodies’ internal rhythms make certain diseases worse at certain times of the day, and in turn affect how to time treatments.

While the Italian study is too small for proof, similar studies from Europe also back a bedtime switch for non-dippers. The work is catching the attention of U.S. hypertension specialists, and now doctors at Baltimore’s Johns Hopkins University are planning a larger study to see if a bedtime switch really could give certain people healthier hearts and kidneys.

How big a problem is non-dipping?

“I think it’s huge,” says Hopkins’ Dr. Lawrence Appel. “This is our best lead” into why black Americans with kidney disease, in particular, tend to worsen despite treatment.

Appel found 80 percent of black kidney patients in a recent study were non-dippers. Most startling, 40 percent had nighttime blood pressure that was even higher than daytime levels.

Two-thirds of chronic kidney disease patients, and at least 10 percent of the general population, are estimated to be non-dippers, says Dr. Joseph Vassalotti of the National Kidney Foundation. One theory is that their bodies have trouble excreting salt.

Yet few patients have ever heard of the problem — and few doctors know who is affected. Most people get their blood pressure checked only during the day. A 24-hour blood pressure monitor can tell but is rarely used, partly because insurance seldom pays for the extra visit to download and diagnose the readings.

And most patients who take several once-a-day pills swallow them all in the morning, meaning they all start wearing off around the same time, says Dr. Gina Lundberg of St. Joseph’s Hospital in Atlanta.

“It does make good sense to take some in the morning and some in the evening,” says Lundberg, a spokeswoman for the American Heart Association.

Everyone has an internal clock, determined by genes, that affects health. Many of these biological rhythms are circadian, meaning they fluctuate on a 24-hour cycle.

Consider how that can affect the timing of treatments. Some older “statin” pills fight cholesterol best if taken at bedtime; they target a liver enzyme that’s most active at night. Asthma attacks are more frequent at night, and the stomach secretes more heartburn-causing acid at night, affecting some patients’ dosing requirements. Researchers even are studying how to better time certain cancer chemotherapies and allergy treatments.

The best-known example: Blood pressure jumps in the early morning hours, as the awakening body produces more stress hormones. That’s also why heart attacks and strokes are most common in the morning.

The nighttime dipping problem has gotten far less attention. The new Italian study marks an important advance, says Dr. Mahboob Rahman of the University Hospitals of Cleveland.

“We know now that you can change medication timing and lower blood pressure at night,” he explains.

That doesn’t mean everyone should switch willy-nilly to bedtime dosing. Morning may be best for people on just one drug, and no one yet knows if the switch truly gives non-dippers better overall health. “That’s the million-dollar question,” Rahman cautions.

Still, Lundberg says it’s worth asking your doctor how to time doses, saying one at night for someone taking multiple medicines couldn’t hurt.

See also:

Keep Timing the Tablets: Statistical Analysis of Pill Dissolution Rates Martin J. Crowder

Abstract

The way in which medicinal tablets, pills and capsules dissolve in liquid is important in the pharmaceutical industry, which collects and analyses data to assess the effects of different formulations of a medicine, different storage conditions, etc. The data usually comprise repeated measures, the record for an individual tablet consisting of either the fractions dissolved at a given sequence of time points or the times taken for given fractions to dissolve. (more…)

Levitra for men with ED and dyslipidemia

Friday, December 14th, 2007

LevitraSchering-Plough said the results of a first prospective trial specifically designed to evaluate erectile function in erectile dysfunction (ED) patients with dyslipidemia showed that Levitra (vardenafil HCl), used in treating ED, significantly improves the ability of men with ED and dyslipidemia to achieve and maintain an erection for successful sexual intercourse.

The double-blind, placebo-controlled study is the first study to measure the safety and efficacy of a PDE 5 inhibitor in a cohort of men who all had ED and dyslipidemia. Results from the study of 395 men show that Levitra significantly increased rates of penetration (as measured by SEP2 scores) and the ability to maintain an erection (as measured by SEP3 scores) compared to placebo.

“ED is associated with high cholesterol, yet many physicians are not treating ED, a life-changing condition,” said Dr Martin Miner, clinical associate professor, Family Medicine, Brown University’s Warren Alpert School of Medicine. “This study provides further support that Levitra can successfully treat ED, even in men with a serious common condition like high cholesterol.”

Nearly 70 per cent of the estimated 30 million men in the United States who have ED also have other common conditions such as dyslipidemia (including high cholesterol), hypertension, or diabetes, which may lead to erectile dysfunction. Previous studies have demonstrated the efficacy and safety of Levitra in men with ED who also have high blood pressure or diabetes.

In the double-blind, placebo-controlled study, 395 men ages 18 to 64 that had ED and dyslipidemia were randomised to treatment with Levitra or placebo for 12 weeks.

Men treated with Levitra had statistically significant and clinically relevant improvements in SEP2 scores (a rating system that measures penetration) and SEP3 scores (a rating system that measures maintenance of erection) versus placebo (79.1 per cent and 66.7 per cent, respectively, for Levitra, vs. 51.9 per cent and 33.8 per cent, respectively, for placebo). IIEF-EF (International Index of Erectile Function) scores also were significantly higher for the Levitra group compared to the placebo group. These scores are evaluated based on a patient questionnaire and their daily diary response to specific questions about sexual performance.

Treatment-emergent adverse effects (occurring in = 5 per cent of patients) included headaches (9 per cent for Levitra, 1 per cent for placebo) and upper respiratory tract infections (5 per cent for Levitra, 3 per cent for placebo).

Erectile dysfunction (ED) is the consistent or recurrent inability of a man to attain and/or maintain a penile erection sufficient for sexual performance. ED can be a total inability to achieve an erection, an inconsistent ability to do so, or a tendency to sustain only brief erections. It is estimated that some degree of ED affects up to 30 million men in the United States.

Some of the most common treatments for ED include adjustments to lifestyle and better control of concomitant medical conditions as well as the use of oral medications or other forms of therapy. Treating related health conditions or reducing stress may help maintain erectile function.

Levitra (vardenafil HCl) is a prescription medicine that is indicated to treat erectile dysfunction (ED). Consistent with the effects of PDE5 inhibition, administration of Levitra with nitrates and nitric oxide donors is contraindicated.

In clinical trials, the most commonly reported adverse events with LEVITRA were headache, flushing, and rhinitis. Adverse events were generally transient.

Nonarteritic anterior ischemic optic neuropathy (NAION) has been reported rarely postmarketing in temporal relationship with the use of PDE5 inhibitors, including Levitra. Sudden loss of hearing, sometimes with tinnitus and dizziness, also has been reported rarely in temporal association with the use of PDE5 inhibitors, including Levitra. It is not possible to determine if these events are related to PDE5 inhibitors or to other factors. Physicians should advise patients to stop use of PDE5 inhibitors, including Levitra, and seek prompt medical attention in the event of sudden loss of vision or hearing.

The recommended starting dose of Levitra is 10 mg. Titrate up to 20 mg or down to 5 mg based on efficacy and side effects.

You can also get some info about Levitra, its safety information, side effects and prices HERE or HERE.

Consumer Information

Generic Name: vardenafil
Brand Names: Levitra
What is Levitra?

Levitra relaxes muscles and increases blood flow to particular areas of the body.

Levitra is used to treat erectile dysfunction (impotence).

Levitra may also be used for purposes other than those listed in this medication guide.

Important information about Levitra
Do not take Levitra if you are also using a nitrate drug for chest pain or heart problems. This includes nitroglycerin (Nitrostat, Nitrolingual, Nitro-Dur, Nitro-Bid, and others), isosorbide dinitrate (Dilatrate-SR, Isordil, Sorbitrate), and isosorbide mononitrate (Imdur, ISMO, Monoket). Nitrates are also found in some recreational drugs such as amyl nitrate or nitrite (”poppers”). Taking Levitra with a nitrate medicine can cause a serious decrease in blood pressure, leading to fainting, stroke, or heart attack. If you become dizzy or nauseated, or have pain, numbness, or tingling in your chest, arms, neck, or jaw during sexual activity, stop and call your doctor right away. You could be having a serious side effect of Levitra. Do not take this medication more than once a day. Allow 24 hours to pass between doses. Contact your doctor or seek emergency medical attention if your erection is painful or lasts longer than 4 hours. A prolonged erection (priapism) can damage the penis.

A small number of patients have had a sudden loss of eyesight after taking Levitra. This type of vision loss is caused by decreased blood flow to the optic nerve of the eye. It is not clear whether Levitra is the actual cause of such vision loss. Sudden vision loss with Levitra use has occurred most often in people with heart disease, diabetes, high blood pressure, high cholesterol, or certain pre-existing eye problems, and in those who smoke or are over 50 years old.

Stop using Levitra and get emergency medical help if you have sudden vision loss.

Before taking Levitra
Do not take Levitra if you are also using a nitrate drug for chest pain or heart problems. This includes nitroglycerin (Nitrostat, Nitrolingual, Nitro-Dur, Nitro-Bid, and others), isosorbide dinitrate (Dilatrate-SR, Isordil, Sorbitrate), and isosorbide mononitrate (Imdur, ISMO, Monoket). Nitrates are also found in some recreational drugs such as amyl nitrate or nitrite (”poppers”). Taking this medication with a nitrate medicine can cause a serious decrease in blood pressure, leading to fainting, stroke, or heart attack.

A small number of patients have had a sudden loss of eyesight after taking Levitra. This type of vision loss is caused by decreased blood flow to the optic nerve of the eye. It is not clear whether Levitra is the actual cause of such vision loss. Sudden vision loss with Levitra use has occurred most often in people with heart disease, diabetes, high blood pressure, high cholesterol, or certain pre-existing eye problems, and in those who smoke or are over 50 years old.

Before taking this medication, tell your doctor if you have:

  • heart disease or heart rhythm problems;
  • a recent history (in the past 6 months) of a heart attack, angina (chest pain), or congestive heart failure;
  • a history of stroke or blood clots;
  • a personal or family history of “Long QT syndrome”;
  • high or low blood pressure;
  • liver disease;
  • kidney disease (or if you are on dialysis);
  • a blood cell disorder such as sickle cell anemia, multiple myeloma, or leukemia;
  • a bleeding disorder such as hemophilia;
  • a stomach ulcer;
  • retinitis pigmentosa (an inherited condition of the eye);
  • a physical deformity of the penis (such as Peyronie’s disease); or
  • if you have been told you should not have sexual intercourse for health reasons.

Levitra side effects

If you become dizzy or nauseated, or have pain, numbness, or tingling in your chest, arms, neck, or jaw during sexual activity, stop and call your doctor right away. You could be having a serious side effect of Levitra. Stop using Levitra and get emergency medical help if you have sudden vision loss. Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using Levitra and call your doctor at once if you have any of these serious side effects:

  • chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
  • irregular heartbeat;
  • swelling in your hands, ankles, or feet;
  • shortness of breath;
  • vision changes;
  • feeling light-headed, fainting; or
    penis erection that is painful or lasts 4 hours or longer.

Continue taking this medication and talk with your doctor if you have any of these less serious side effects:

  • warmth or redness in your face, neck, or chest;
  • stuffy nose;
  • headache;
  • upset stomach; or
  • back pain.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

What other drugs will affect Levitra?

Before taking Levitra, tell your doctor if you are using any of the following medications:

  • cimetidine (Tagamet, Tagamet HB);
  • erythromycin (E-Mycin, Eryc, Ery-Tab) or clarithromycin (Biaxin);
  • doxazosin (Cardura), prazosin (Minipress), terazosin (Hytrin);
  • HIV medicines such as amprenavir (Agenerase), tipranavir (Aptivus), darunavir (Prezista), efavirenz (Sustiva), nevirapine (Viramune), indinavir (Crixivan), saquinavir (Invirase, Fortovase), lopinavir/ritonavir (Kaletra), fosamprenavir (Lexiva), ritonavir (Norvir), atazanavir (Reyataz), or nelfinavir (Viracept);
  • itraconazole (Sporanox) or ketoconazole (Nizoral);
  • heart rhythm medicine such as amiodarone (Cordarone, Pacerone), quinidine(Quinidex, Quinaglute), procainamide (Procan, Pronestyl), or sotalol (Betapace);
  • carbamazepine (Tegretol), phenobarbital (Luminal), or phenytoin (Dilantin); or
  • rifampin (Rifadin, Rimactane).

If you are using any of these drugs, you may not be able to take Levitra, or you may need dosage adjustments or special tests during treatment.

There may be other drugs not listed that can affect Levitra. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

Merck recalled Pedvaxhib and Comvax

Friday, December 14th, 2007

Merck recalls Comvax and PedvaxhibMerck & Co., Inc. said it voluntarily recalled 13 lots of its Hib vaccine given to ankle-biters to prevent meningitis and pneumonia as quality control found production equipment may not have been properly sterilised.

Merck recalled 11 lots of Pedvaxhib [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)], and two lots of its combination Haemophilus influenzae type B/ hepatitis B vaccine, Comvax [Haemophilus b Conjugate (Meningococcal Protein Conjugate)]. The recall is specific to these 13 lots and does not affect any other vaccines manufactured by Merck. The affected doses of Pedvaxhib and Comvax were distributed starting in April 2007.

The company said the recall is because it can not assure sterility of these specific vaccine lots. The potential contamination of these specific lots was identified as part of the company’s standard evaluation of its manufacturing processes. Sterility tests of the vaccine lots that are the subject of this recall have not found any contamination in the vaccine.

The potential for contamination of any individual vaccine is low, and, if present, the level of contamination would be low. However, because the company cannot assure the sterility of these specific lots of vaccine, it is conducting this recall.

Merck is working closely with the US Food and Drug Administration (FDA) and the US Centres for Disease Control and Prevention (CDC) to inform affected healthcare providers of this recall. The company is also communicating with public health authorities and healthcare providers in the US and in other countries where these lots were distributed, as appropriate.

“We are taking this action because we are committed to ensuring the quality of our vaccines,” said Mark Feinberg, MD, Ph.D., vice president, medical and policy affairs, Merck vaccines and infectious diseases. “We know that our vaccines can play an important role in the nation’s public health system, and we are committed to resolving this issue as quickly as possible to ensure that our vaccines are readily available.”

Physicians are advised not to administer any vaccine from the vaccine lots being recalled. Individuals who received vaccine from these lots should complete their immunization series with a Haemophilus b conjugate-containing vaccine not affected by this recall, but do not need to be revaccinated to replace a dose they received from a recalled lot. The efficacy of the vaccine was not affected, the company officials said in a press statement.

Pedvaxhib is indicated for routine vaccination against invasive disease caused by Haemophilius influenzae type b in infants and children two to 71 months of age. As with any vaccine, the use of Pedvaxhib may not result in a protective antibody response in all vaccines; Pedvaxhib may not induce protective antibody levels immediately following vaccination.

Comvax [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine] is indicated for vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants six weeks to 15 months of age born to HBsAg-negative mothers.

Comvax is contraindicated in patients with hypersensitivity to yeast or any component of the vaccine. Comvax included injection-site reactions, somnolence, irritability, crying, and fever.

As with other vaccines, Comvax may not induce protective antibody levels immediately following vaccination and may not result in a protective antibody response in all individuals given the vaccine.

General information about Haemophilus b Conjugate Vaccine

Some commonly used brand names in the U.S. and Canada are:

  • Act-Hib
  • Hibtiter
  • Pedvaxhib
  • Prohibit

Category: Immunizing agent, active

Description

(more…)

Blood pressure drug Telmisartan - no more strokes!

Thursday, December 13th, 2007

Telmisartan (Micardis)Telmisartan, a drug widely used to help control blood pressure, may have uniquely potent activity in preventing stroke, according to a new study conducted in an animal model.

Whether they used the drug alone or in combination with a different type of antihypertensive medication, ramipril, Weill Cornell Medical College researchers found that rats fed a high-salt, stroke-inducing diet were completely protected from the brain attacks while on telmisartan.

“No other study has ever shown complete protection against stroke in this rat model using normal human drug doses” notes study senior author Dr. Daniel F. Catanzaro, professor of physiology and biophysics and professor of physiology in cardiothoracic surgery at Weill Cornell Medical College.

The study, which was funded by telmisartan’s German maker, Boehringer Ingelheim Pharma GmbH & Co., is published online in the Journal of the American Society of Hypertension.

Telmisartan (brand name Micardis) is one of a class of widely used antihypertensive drugs known as angiotensin receptor blockers (ARBs). “These drugs primarily act on the vasculature to relax the small blood vessels,” Dr. Catanzaro explains.

Telmisartan stands out from other ARBs in that its molecular structure allows it to more easily pass through the blood-brain barrier and enter the brain — something many drugs cannot do.

The new animal study was not constructed to specifically look at telmisartan’s effect on stroke. “Because blood pressure is closely related to stroke risk, we really just wanted to look and see if combinations of antihypertensive drugs were better at lowering blood pressure and stroke compared to the use of single agents,” Dr. Catanzaro explains.

In this case, his team tested two drugs — telmisartan and an ACE inhibitor, ramipril (Altace) — in a rat model long favored by stroke researchers. In this approach, rats are fed what’s known as a “stroke-prone diet,” meaning they get lots of salt in both their food and water.

“This rat model has been great at showing us the neuroprotective properties of different drugs in the past, and the results usually correlate with results in humans,” Dr. Catanzaro says.

In the study, 25 rats were fed the stroke-prone diet for 8 weeks and received either no medication, telmisartan alone, ramipril alone, or the two drugs together at either full- or half-doses.

“A main finding was that combination therapy did reduce blood pressure the best of any treatment, and it also was best at cutting damage to the rats’ hearts and kidneys,” Dr. Catanzaro says. “But what was really surprising to us was that any regimen involving telmisartan at doses that would normally be given to humans completely prevented stroke in this model. Most studies with other drugs have used much higher doses and have found only partial protection.”

Specifically, 83 percent of rats given no medication showed signs of stroke, as did 56 percent of rats given ramipril alone. However, no strokes were noted in the telmisartan-only or the telmisartan/ramipril combo groups.

Telmisartan’s ability to easily pass through the blood-brain barrier (something ramipril cannot do) is likely behind the neuroprotective effect noted in the study, the researchers say.

“Going forward, that’s something that we would really like to test out in head-to-head trials pitting telmisartan against other ARBs, for example,” Dr. Catanzaro said. “At the same time, we’d like to examine whether telmisartan is actually getting into the brain, or if more peripheral effects — a lowering of blood pressure, for instance — are behind the reduction in stroke.”

In the meantime, Boehringer Ingelheim is nearing the end of a major clinical trial looking at the effectiveness of combining telmisartan with ramipril to lower patients’ blood pressures and reduce their odds for heart attack and stroke. Dr. Catanzaro’s team is not involved in that study.

Co-authors on this study include lead researcher Dr. Ying Zhou, as well as Dr. Fangmin Yu and Dr. Ada R. Ene — all of Weill Cornell Medical College in New York City.

Telmisartan information.

GENERIC NAME: Telmisartan
BRAND NAME: Micardis

DRUG CLASS AND MECHANISM: Telmisartan is a member of a family of drugs called angiotensin receptor blockers (ARBs), which includes losartan (Cozaar), valsartan (Diovan), irbesartan (Avapro), and candesartan (Atacand). ARBs block the ability of the chemical angiotensin II to constrict or squeeze arteries and veins. As a result, the arteries and veins enlarge and blood pressure falls. The reduced pressure in the arteries also makes it easier for the heart to pump blood. Telmisartan was approved by the FDA in November of 2000.

USES: This drug is used to treat high blood pressure (hypertension). This drug works by blocking the hormone angiotensin thereby relaxing blood vessels, causing them to widen. High blood pressure reduction helps prevent strokes, heart attacks, and kidney problems.

OTHER USES: This drug may also be used to treat congestive heart failure and to help protect the kidneys from damage due to diabetes.

HOW TO USE: Take this medication by mouth, usually once daily or as directed by your doctor. You may take this drug with or without food. Use this medication regularly in order to get the most benefit from it. To help you remember, use it at the same time each day. Do not take potassium supplements or salt substitutes containing potassium without talking to your doctor or pharmacist first. This medicine can raise your potassium levels, which rarely can cause serious side effects such as muscle weakness or very slow heartbeats. Tell your doctor immediately if these effects occur. The dosage is based on your medical condition and response to therapy. For the treatment of high blood pressure, it may take 4 weeks before the full benefit of this drug occurs. It is important to continue taking this medication even if you feel well. Most people with high blood pressure do not feel sick.

SIDE EFFECTS: You may experience dizziness, lightheadedness, blurred vision, or back pain as your body adjusts to the medication. If any of these effects persist or worsen, notify your doctor or pharmacist promptly. Tell your doctor immediately if any of these unlikely but serious side effects occur: fainting, decreased sexual ability. Tell your doctor immediately if any of these highly unlikely but very serious side effects occur: change in the amount of urine. An allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of an allergic reaction include: rash, itching, swelling (especially of the face, lips, tongue, or throat), severe dizziness, trouble breathing. If you notice other effects not listed above, contact your doctor or pharmacist.

WARNING: This drug can cause serious fetal harm (possibly death) if used during the last six months of pregnancy. If you become pregnant or think you may be pregnant, contact your doctor immediately.

Avandia heart risks

Wednesday, December 12th, 2007

Avandia risksThe findings of clinical trials have linked the use of thiazolidinediones, a class of diabetes drugs, with congestive heart failure and possibly heart attacks. Now, new research indicates that these associations, at least with Avandia, also apply to individuals in the community, and not just clinical trials.

Dr. Lorraine L. Lipscombe, from the Institute for Clinical Evaluative Sciences in Toronto, and colleagues analyzed data for 159,026 older adults who were treated with at least one oral diabetes drug between 2002 and 2005 and were entered in an Ontario healthcare database. The subjects were followed through March 2006.

During an average follow-up period of 3.8 years, 7.9 percent of the patients were hospitalized for congestive heart failure, 7.9 percent were hospitalized for a heart attack, and 19 percent died, according to the researchers’ report in Journal of the American Medical Association.

Current thiazolidinediones use increased the risks of heart failure, heart attack and death by 60 percent, 40 percent, and 29 percent, respectively, compared with the use of other types of oral diabetes drugs.

Further analysis revealed that the risks were largely confined to patients who were using Avandia, known generically as rosiglitazone.

“These findings provide evidence from a real-world setting and support data from clinical trials that the harms of thiazolidinediones may outweigh their benefits, even in patients without obvious…cardiovascular disease,” the authors write.

More studies are needed to better define the risk-benefit ratio and the trade-offs associated with thiazolidinedione therapy and to explore if the treatment risks are confined specifically to rosiglitazone.

Avandia risks highlighted

Canadian researchers furnished the strongest evidence to date linking the popular diabetes drug Avandia to an increased risk of heart attack in a scientific study released yesterday.

Compared with other diabetes pills, Avandia’s use was associated with a 60 percent higher risk of heart failure, 40 percent higher risk of heart attack and 30 percent higher risk of death in patients 65 and older, the researchers found.

“The risks associated with these drugs may outweigh the benefits, at least for older populations,” said Dr. Lorraine L. Lipscombe, the lead author of the study and a researcher at a health research agency funded by the Ontario government.

The findings, published in the influential Journal of the American Medical Association, will probably intensify pressure on the government to restrict sales of the oral diabetes medicine.

“It should come off the market,” said Dr. Sidney M. Wolfe, director of health research at Public Citizen, a liberal interest group preparing to petition the Food and Drug Administration to pull the drug.

Sales of Avandia have plummeted since Dr. Steven Nissen, a prominent cardiologist, reported in May that it raised the risk of heart attack. His report prompted congressional hearings and demands to stop sales.

The FDA decided against that last month, instead adding a label warning that urges users to consult a doctor if they have serious heart problems.

The decision divided agency staff. Ultimately, FDA officials decided the scientific evidence wasn’t conclusive, and they asked Avandia’s manufacturer to conduct a long-term study.

In a statement, the FDA said it would review the results from the Canadian study, but it needs more evidence before taking any further action. “This new study we have just seen today does not change FDA’s recommendations,” the agency said.

GlaxoSmithKline, Avandia’s maker, dismissed the Canadians’ findings as limited and misleading because the elderly studied might have been at higher risk of heart problems.

The Philadelphia company, which is conducting a long-term study of Avandia’s side effects, said in a statement that many other studies show Avandia is safe and effective.

The new study is the first to review side effects in real patients, rather than test subjects, according to Lipscombe, a researcher at the Institute for Clinical Evaluative Sciences in Toronto.

Beginning in March, Lipscombe and her colleagues analyzed health care records for all elderly Ontario residents who took an oral diabetes medicine between 2002 and 2006.

Lipscombe said they focused on the elderly because 40 percent of diabetes patients in Ontario are 65 and older, but the elderly tend to be underrepresented in scientific drug studies.

The researchers didn’t find a higher heart risk among users of Actos, an Avandia competitor that belongs to the same class of diabetes drugs, but Lipscombe said there weren’t enough Actos users to draw a firm conclusion.

Older Diabetics Using Avandia Face Increased Death Risk

Older patients using the diabetes drug Avandia faced an increased risk of heart attack, heart failure and even death, new research shows.

According to the Canadian authors of the study, which is published in the Dec. 12 issue of the Journal of the American Medical Association, this is the first population-based look at the class of drugs to which Avandia belongs and the first report to find an increase in mortality rates.

“Our study looked at an older population in the real world who tend to be underrepresented in research trials and are at higher risk,” said study author Dr. Lorraine L. Lipscombe, a researcher with the Institute for Clinical Evaluative Sciences in Toronto. “While the overall risk versus benefit is difficult to interpret in all people, in older people, the risks may outweigh the benefit.”

“This is very striking data,” added Dr. Steven Nissen, chairman of the department of cardiovascular medicine at the Cleveland Clinic Foundation. “This and other studies are going to put tremendous pressure on the FDA [U.S. Food and Drug Administration] to act more forcefully with regard to Avandia.”

But the maker of Avandia (rosiglitazone), GlaxoSmithKline, took issue with the findings.

In a prepared statement, the company said the Canadian study “has significant limitations and generates misleading conclusions regarding acute myocardial infarction and death. These conclusions are inconsistent with a more robust body of evidence from large, long-term, prospective, well-designed clinical studies, including ADOPT and RECORD. These long-term trials in diabetic patients comparing rosiglitazone to other oral anti-diabetic medicines show no increased risk for cardiovascular events compared to other commonly used medications, other than the well-known risk of congestive heart failure with thiazolidinedione (TZDs).”

Nissen was the first scientist to publish concerns about Avandia and increased heart risks in a study last May.

After that and other research was released, the FDA added a “black box” warning to all drugs in the class. An FDA advisory panel voted against removing the drug from the market, citing inconclusive evidence.

The Canadian label for Avandia carries a stronger message: The drug is not to be used as the sole medication for type 2 diabetes unless the patient cannot take another drug to lower blood sugar and that the drug should not be used by any patient with heart failure.

People with type 2 diabetes are already at heightened risk for cardiovascular disease.

Thiazolidinediones including Avandia and Actos (pioglitazone) heighten the body’s sensitivity to insulin. Some 3.5 million U.S. patients take Avandia, which has also been linked to bone loss in some patients.

The current study involved an older (66 and over), “real-world” population consisting of more than 159,000 residents of Ontario in this age group who were treated with at least one oral diabetic medication. The patients were followed for about four years.

Compared to individuals taking more than one oral hypoglycemic agent, people using Avandia on its own had a 60 percent increased risk of congestive heart failure, a 40 percent increased risk of heart attack, and a 29 percent increased risk of dying.

The increased risks were associated with Avandia only, but fewer people in the study took Actos, so the results could be skewed, the researchers noted.

“It looks like the results were limited to Avandia, but 50 percent fewer people were on Actos, so you can’t rule out an increased or decreased risk with Actos,” Lipscombe said. “We need more studies.”

“It’s an observational study and, like all observational studies, this has strengths and weaknesses. These studies do not provide the strength of evidence of a prospective, randomized trial,” Nissen pointed out. “But as observational studies go, this one is very helpful, because it is quite large, and it is independent, not sponsored by any company. Remarkably, with Avandia, the increased risk of heart attack is very similar to what we reported in our meta-analysis last May.”

In related research appearing in the same issue of JAMA, a review of 25 studies found that current smokers have a 44 percent increased risk of developing type 2 diabetes compared with nonsmokers.

The degree of risk was linked to the level of smoking — there was a 61 percent increased risk for those smoking 20 or more cigarettes a day and a 29 percent increased risk for those who smoked less, said the Swiss researchers. Former smokers had a 23 percent increased risk.